BioScrip's CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

BioScrip Inc. (BIOS)

Bank of America Merrill Lynch 2012 Health Care Conference Transcript

May 17, 2012 3:40 PM ET

Executives

Rick Smith – President and CEO

Analysts

Presentation

Unidentified Analyst

Compare to:
Previous Statements by BIOS
» BioScrip's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» BioScrip's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» BioScrip's CEO Discusses Q3 2011 Results - Earnings Call Transcript

…this afternoon for, I guess, last but not least for our final presentation of the conference. But with the final presentation we have Rick Smith, the President and CEO of BioScrip. Thank you, Rick for joining us…

Rick Smith

Thank you.

Unidentified Analyst

…and let’s take it away.

Rick Smith

Okay. Good afternoon. Here is a Safe Harbor for your information. The BioScrip has been going under series of steps of transformation over the last 15 months. As of for 2011 our total revenue size is about a $1.8 billion in revenue and as part of our transformation we had made a decision to sell certain parts of our business that represent about a $1.2 billion revenue is more in the areas of our specialty pharmacy and legacy community, specialty pharmacy retail stores, and our traditional mail business.

What we have, last is essentially the focus area and that is Home Infusion, which based on our Q1 2012 revenue about $109 million, a Home Health segment that we acquired through the acquisition of CHS about $16.7 million represented for the quarter. And then one of the remaining segments of our Pharmacy Services is PBM and Cash Card legacy business that generate about $30 million in revenue for Q1 as well.

Our focus now and as we’ve talked about is, is really to becoming national platform in Home Infusion, a lot of the efforts that we’ve essentially put in place over the last couple of years is really to position ourselves from a contracting perspective and also to expand our infusion footprint.

1 2 3 Next › Last »